Treatment with a GPIIb/IIIa Antagonist Inhibits Thrombin Generation in Platelet Rich Plasma from Patients
- 1 January 1998
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 80 (09), 370-371
- https://doi.org/10.1055/s-0037-1615213
Abstract
Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity, inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.Keywords
This publication has 3 references indexed in Scilit:
- Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".JCI Insight, 1996
- Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy menCancer Cell, 1994
- Generation of Prothrombin‐Converting Activity and the Exposure of Phosphatidylserine at the Outer Surface of PlateletsEuropean Journal of Biochemistry, 1982